Compare LCNB & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCNB | WHWK |
|---|---|---|
| Founded | 1877 | 2007 |
| Country | United States | United States |
| Employees | N/A | 23 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.1M | 208.7M |
| IPO Year | 1999 | N/A |
| Metric | LCNB | WHWK |
|---|---|---|
| Price | $16.51 | $4.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 15.6K | ★ 344.2K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.43% | N/A |
| EPS Growth | ★ 68.04 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $6,445,000.00 | N/A |
| Revenue This Year | $8.50 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | $53.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.75 | $1.57 |
| 52 Week High | $17.89 | $5.50 |
| Indicator | LCNB | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 55.52 | 64.16 |
| Support Level | $16.45 | $1.92 |
| Resistance Level | $17.36 | $5.50 |
| Average True Range (ATR) | 0.40 | 0.38 |
| MACD | 0.07 | 0.03 |
| Stochastic Oscillator | 86.64 | 74.52 |
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.